StockData
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc. (NTLA) stock

NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.78−0.08 (-0.81%)

Close on Nov 17, 2026Market cap $1.37BP/E –Yield –

Intellia Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Intellia Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$346.64M. For fiscal 2025 it was -$394.74M. The highest annual figure on record is $36.11M in fiscal 2016.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$394.74M–
FY2024Dec 31, 2024-$348.88M–
FY2023Dec 31, 2023-$394.09M–
FY2022Dec 31, 2022-$333.29M–
FY2021Dec 31, 2021-$225.03M–
FY2020Dec 31, 2020-$49.91M–
FY2019Dec 31, 2019-$103.24M–
FY2018Dec 31, 2018-$61.26M–
FY2017Dec 31, 2017-$65.28M-280.8%
FY2016Dec 31, 2016$36.11M–
FY2015Dec 31, 2015-$1.76M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$83.11M–
Q1 FY2026Mar 31, 2026-$117.35M–
Q4 FY2025Dec 31, 2025-$69.29M–
Q3 FY2025Sep 30, 2025-$76.90M–
Q2 FY2025Jun 30, 2025-$99.62M–
Q1 FY2025Mar 31, 2025-$148.93M–
Q4 FY2024Dec 31, 2024-$85.20M–
Q3 FY2024Sep 30, 2024-$84.84M–
Q2 FY2024Jun 30, 2024-$58.19M–
Q1 FY2024Mar 31, 2024-$120.66M–
Q4 FY2023Dec 31, 2023-$93.05M–
Q3 FY2023Sep 30, 2023-$101.38M–
Q2 FY2023Jun 30, 2023-$90.32M–
Q1 FY2023Mar 31, 2023-$109.33M–
Q4 FY2022Dec 31, 2022-$89.87M–
Q3 FY2022Sep 30, 2022-$78.53M–
Q2 FY2022Jun 30, 2022-$85.09M–
Q1 FY2022Mar 31, 2022-$79.80M–
Q4 FY2021Dec 31, 2021-$54.65M–
Q3 FY2021Sep 30, 2021-$65.02M–
Q2 FY2021Jun 30, 2021-$52.98M-192.3%
Q1 FY2021Mar 31, 2021-$52.38M–
Q4 FY2020Dec 31, 2020-$40.23M–
Q3 FY2020Sep 30, 2020-$28.56M–
Q2 FY2020Jun 30, 2020$57.42M–
Q1 FY2020Mar 31, 2020-$38.55M–
Q4 FY2019Dec 31, 2019-$28.66M–
Q3 FY2019Sep 30, 2019-$25.45M–
Q2 FY2019Jun 30, 2019-$27.68M–
Q1 FY2019Mar 31, 2019-$21.45M–
Q4 FY2018Dec 31, 2018-$8.54M–
Q3 FY2018Sep 30, 2018-$12.45M–
Q2 FY2018Jun 30, 2018-$22.50M–
Q1 FY2018Mar 31, 2018-$17.77M–
Q4 FY2017Dec 31, 2017-$21.31M–
Q3 FY2017Sep 30, 2017-$16.89M–
Q2 FY2017Jun 30, 2017-$15.68M–
Q1 FY2017Mar 31, 2017-$11.40M–
Q4 FY2016Dec 31, 2016-$14.41M–
Q3 FY2016Sep 30, 2016-$7.61M–

More Intellia Therapeutics figures

See a number that looks wrong?